Based on the exciting finding on the powerful value of LAG-3 as serum biomarker for predicting tumor response to TACE therapy, we continued to evaluate the prognostic significances of pretreatment serum levels of LAG-3 and PD-L1. This evidence concerns the gene CD274 and neoplasm.